Evidence map›Paper›PMID 39759507›Full record

ArticleFrontiers in immunology2024

Unveiling the NEFH+ malignant cell subtype: Insights from single-cell RNA sequencing in prostate cancer progression and tumor microenvironment interactions.

Jie Wang, Fu Zhao, Qiang Zhang, Zhou Sun, Zhikai Xiahou, Changzhong Wang, Yan Liu, Zongze Yu

Erratum issuedAbstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Spatial Transcriptomics Reveals Location-Specific Tumor Cell Subtypes and Signaling within Multifocal Small Intestinal Neuroendocrine Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  3. Article
  4. Article
  5. Integrative multi-omics reveals the POSTNFrontiers in immunology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Jie Wang *Department of Urology, The Second People's Hospital of Meishan City, Meishan, Sichuan, China.
Fu Zhao *The First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, China.
Qiang Zhang *Department of Urology, The Second People's Hospital of Meishan City, Meishan, Sichuan, China.
Zhou Sun *Department of Urology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Zhikai XiahouChina Institute of Sport and Health Science, Beijing Sport University, Beijing, China.
Changzhong WangDepartment of Urology, The First People's Hospital of Jiangxia District, Wuhan, Hubei, China.
Yan LiuDepartment of Urology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China.
Zongze YuDepartment of Urology, The Second People's Hospital of Meishan City, Meishan, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Prostate cancer (PCa) is a multifactorial and heterogeneous disease, ranking among the most prevalent malignancies in men. In 2020, there were 1,414,259 new cases of PCa worldwide, accounting for 7.3% of all malignant tumors. The incidence rate of PCa ranks third, following breast cancer and lung cancer. Patients diagnosed with high-grade PCa frequently present with existing or developing metastases, complicating their treatment and resulting in poorer prognoses, particularly for those with bone metastases. Utilizing single-cell RNA sequencing (scRNA-seq), we identified specific malignant cell subtypes that are closely linked to high-grade PCa. By investigating the mechanisms that govern interactions within the tumor microenvironment (TME), we aim to offer new theoretical insights that can enhance the prevention, diagnosis, and treatment of PCa, ultimately striving to improve patient outcomes and quality of life. Methods: Data on scRNA-seq was obtained from the GEO database. The gene ontology and gene set enrichment analysis were employed to analyze differential expression genes. Using inferCNV analysis to identify malignant epithelial cells. We subsequently employed Monocle, Cytotrace, and Slingshot packages to infer subtype differentiation trajectories. The cellular communication between malignant cell subtypes and other cells was predicted using the CellChat package. Furthermore, we employed pySCENIC to analyze and identify the regulatory networks of transcription factors (TFs) in malignant cell subtypes. The MDA PCa 2b and VCap cell lines were employed to validate the analysis results through cellular functional experiments. In addition, a risk scoring model was developed to assess the variation in clinical characteristics, prognosis, immune infiltration, immune checkpoint, and drug sensitivity. Results: A malignant cell subtype in PCa with high expression of Conclusion: By examining the cellular heterogeneity of a unique

Indexed as

Disease ProgressionProstatic NeoplasmsSingle-Cell AnalysisTumor MicroenvironmentBiomarkers, TumorCancer-Associated FibroblastsCell Line, TumorGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleSequence Analysis, RNATranscriptomeBiomarkers, Tumordrug discoverymulti-omicsprecision medicineprostate cancersingle-cell RNA sequencingtumor heterogeneity

Identifiers

PMID39759507
PMCPMC11695424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.